Associations between substance use and symptomatic Long COVID in the Researching COVID to Enhance Recovery (RECOVER)‐adult cohort study
Addiction · 13.11.2026
DOI: 10.1111/add.70693 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Addiction, online erschienen am 13.11.2026. Verfasst von Chukwuemeka N Okafor und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio,…. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aims
To determine whether frequency of tobacco, cannabis and binge alcohol use in the 12 months prior to SARS‐CoV‐2 test result or COVID‐19 symptom onset is associated with (1) presence of symptomatic Long COVID at study entry and (2) development of symptomatic Long COVID over 12 months of follow‐up, among those without Long COVID at study entry.
Design
Prospective cohort study with cross‐sectional and longitudinal components.
Setting
Multi‐site study conducted across 83 clinical sites in the United States.
Participants
A total of 9477 adults enrolled between October 2021 and July 2024 (median age 43 years; 74% female).
Measurements
Self‐reported frequency of tobacco product, cannabis and binge alcohol use in the 12 months prior to SARS‐CoV‐2 test infection (never, monthly or less, weekly or none). Symptomatic Long COVID was defined using the Researching COVID to Enhance Recovery (RECOVER)‐Adult Long COVID Research Index, with scores ≥ 11 classified as symptomatic Long COVID and lower scores classified as indeterminate. Covariates included sociodemographic characteristics, clinical comorbidities and COVID‐19 related factors.
Results
At study entry 20% of participants met criteria for symptomatic Long COVID. In the 12 months preceding infection, 14%, 21% and 38% reported any tobacco product, cannabis or binge alcohol use. At study entry, compared with no use, weekly or more tobacco use was associated with higher odds of symptomatic Long COVID [adjusted odds ratio (aOR) = 1.37, 95% confidence interval (CI) = 1.13–1.67]; weekly or more cannabis use was associated with higher odds of symptomatic Long COVID (aOR = 1.23, 95% CI = 1.00–1.52); and weekly or more binge alcohol use was associated with lower odds (aOR = 0.73, 95% CI = 0.58–0.91) of symptomatic Long COVID. Monthly or less use of any substance was not associated with symptomatic Long COVID at study entry. Among participants without symptomatic Long COVID at study entry, weekly or more tobacco use, compared with no use, was associated with higher odds of developing symptomatic Long COVID over 12 months of follow‐up (aOR = 1.29, 95% CI = 1.03–1.62). Neither cannabis nor binge alcohol use was statistically significantly associated with symptomatic Long COVID at 12‐month follow‐up. Summary Among adult participants of the Researching COVID to Enhance Recovery (RECOVER) study, weekly or more tobacco use in the 12 months prior to SARS‐CoV‐2 infection was associated with higher odds of symptomatic Long COVID at study entry and at 12 months among participants who did not meet criteria for symptomatic Long COVID at study entry. Weekly or more cannabis use was associated with higher odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months. Weekly or more binge alcohol use was associated with lower odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
- Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
- Department of Medicine, Division of Pulmonary Sciences and Critical Care, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
- Department of Medicine, Division of Infectious Disease, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
- RECOVER Patient, Caregiver, or Community Representative, USA.
- Department of Psychiatry and Behavioral Sciences, Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
ORCID-Profile: Chukwuemeka N Okafor, Ryan Peterson, Kristine M Erlandson, Brittany D Taylor, Leah Castro, Barbara S Taylor, Jennifer S Potter
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Okafor, C. N., Peterson, R., Nepple, C., Jolley, S., Erlandson, K. M., Taylor, B. D., Castro, L., Aragon, L., Roberts, M., Lewis, J., Akintonwa, T., Taylor, B. S., Potter, J. S., Patterson, T. F., Burnham, E. L., & RECOVER Consortium (2026). Associations between substance use and symptomatic Long COVID in the Researching COVID to Enhance Recovery (RECOVER)‐adult cohort study. Addiction. https://doi.org/10.1111/add.70693
Vancouver
Okafor CN, Peterson R, Nepple C, Jolley S, Erlandson KM, Taylor BD, et al. Associations between substance use and symptomatic Long COVID in the Researching COVID to Enhance Recovery (RECOVER)‐adult cohort study. Addiction. 2026. doi:10.1111/add.70693
BibTeX
@article{Okafor2026,
author = {Okafor, Chukwuemeka N and Peterson, Ryan and Nepple, Cecilia and Jolley, Sarah and Erlandson, Kristine M and Taylor, Brittany D and Castro, Leah and Aragon, Leyna and Roberts, Marjorie and Lewis, Juan and Akintonwa, Teresa and Taylor, Barbara S and Potter, Jennifer S and Patterson, Thomas F and Burnham, Ellen L and RECOVER Consortium, RECOVER Consortium},
title = {Associations between substance use and symptomatic Long COVID in the Researching COVID to Enhance Recovery (RECOVER)‐adult cohort study},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70693}
}
EUVIMED